Lynkuet (elinzanetant), a non-hormonal treatment for vasomotor symptoms (VMS) associated with menopause, will be available in Germany starting April 1st, 2026, following successful Phase III clinical trials and European Medicines Agency (EMA) approval. This new option offers relief for women experiencing hot flashes and night sweats without the use of traditional hormone therapy and builds on approvals already granted in the US, Australia, Canada, and the UK.
The arrival of Lynkuet represents a significant advancement in managing menopausal symptoms, particularly for women who are ineligible for or prefer to avoid hormone therapy. Menopause, a natural biological process marking the complete of a woman’s reproductive years, affects approximately 75-80% of women, with VMS being among the most disruptive symptoms. These symptoms, characterized by sudden feelings of warmth, sweating, and often sleep disturbances, can significantly impact quality of life. Current treatment options are limited, and Lynkuet provides a novel, targeted approach to symptom management.
In Plain English: The Clinical Takeaway
- New Option for Hot Flashes: Lynkuet is a daily pill that can reduce the number and severity of hot flashes without using estrogen.
- How it Works: It blocks specific signals in the brain that control body temperature, helping to stabilize it and reduce those uncomfortable temperature swings.
- Who Can Use It: It’s particularly helpful for women who can’t or don’t want to take hormone therapy, including those with a history of breast cancer.
The Oasis Clinical Trial Series: A Deep Dive into Efficacy and Safety
The European approval of Lynkuet is based on the comprehensive Oasis clinical trial program, encompassing four Phase III studies (Oasis 1-4) involving over 1800 postmenopausal women across more than 180 international sites. Participants were selected based on experiencing moderate to severe VMS, defined as at least 7 to 50 hot flashes per day, or at least 50 episodes per week. The trials were designed as randomized, double-blind, placebo-controlled studies – meaning participants were randomly assigned to receive either Lynkuet or a placebo (an inactive pill), and neither the participants nor the researchers knew who was receiving which treatment until the study was completed. This rigorous methodology minimizes bias and ensures the reliability of the results.
Studies Oasis-1 and Oasis-2 demonstrated a statistically significant reduction in the frequency and intensity of hot flashes compared to placebo, with improvements observed as early as the first week of treatment and sustained through 4 and 12 weeks. Importantly, the trials also showed improvements in sleep quality and overall quality of life. Oasis-3 assessed the long-term safety of Lynkuet over a year, involving 628 participants consistently receiving a 120mg daily dose. Oasis-4 specifically focused on women receiving adjuvant endocrine therapy for breast cancer, confirming both efficacy and safety in this population. The mechanism of action centers around elinzanetant’s role as a dual neurokinin-1,3 receptor antagonist. Neurokinin receptors play a crucial role in regulating body temperature and sleep, and their dysregulation contributes to VMS during menopause. By blocking these receptors, Lynkuet helps restore balance and alleviate symptoms.
Understanding Elinzanetant: A Novel Neurokinin Receptor Antagonist
Elinzanetant belongs to a class of drugs called neurokinin receptor antagonists. These drugs work by blocking the action of neurokinin B (NKB), a neurotransmitter that becomes elevated during menopause and is believed to play a key role in triggering hot flashes. NKB binds to two receptors in the hypothalamus – the neurokinin 1 (NK1) and neurokinin 3 (NK3) receptors – which regulate body temperature and sleep. During estrogen deficiency, the NK3 receptor becomes overactive, leading to inappropriate activation of the body’s temperature control center. The NK1 receptor mediates the physical responses to these temperature changes, such as vasodilation (widening of blood vessels) and sweating. Elinzanetant simultaneously blocks both NK1 and NK3 receptors, effectively dampening the signals that cause hot flashes and sleep disturbances. This dual action distinguishes it from other potential therapies targeting only one receptor.
The development of Lynkuet was funded by Bayer AG, the pharmaceutical company that holds the marketing authorization. Transparency regarding funding sources is crucial for evaluating potential biases in research. As Dr. Paula Hillard, Professor of Obstetrics and Gynecology at Stanford University, noted in a recent interview, “The dual antagonism of NK1 and NK3 receptors represents a significant step forward in non-hormonal menopause treatment, offering a targeted approach to symptom relief with a potentially favorable safety profile.”
“This is a welcome addition to the toolkit for managing menopausal symptoms, particularly for women who cannot or choose not to use hormone therapy.” – Dr. Paula Hillard, Stanford University.
| Trial Phase | Participants (N) | Primary Endpoint | Key Findings |
|---|---|---|---|
| Oasis 1 | ~400 | Reduction in hot flash frequency | Statistically significant reduction compared to placebo (p<0.001) |
| Oasis 2 | ~400 | Reduction in hot flash severity | Statistically significant reduction compared to placebo (p<0.001) |
| Oasis 3 | 628 | Long-term safety (1 year) | Well-tolerated with no new safety signals |
| Oasis 4 | 474 | Efficacy in women with breast cancer | Confirmed efficacy and safety in this population |
Geographical Access and Regulatory Pathways
Lynkuet’s approval pathway highlights the varying regulatory landscapes across different regions. The drug was first approved in the United States, Australia, Canada, and the United Kingdom in September 2025, following submissions to their respective regulatory agencies (FDA, TGA, Health Canada, and MHRA). The EMA approval paves the way for its rollout across the European Union, with Germany being among the first countries to make it available. Applications for marketing authorization are currently under review in other global markets. The EMA’s centralized approval process allows for a single assessment that is valid across all EU member states, streamlining access for patients. However, individual countries may have their own pricing and reimbursement policies, which can influence the speed and extent of adoption. The National Institute for Health and Care Excellence (NICE) in the UK, for example, will likely evaluate Lynkuet’s cost-effectiveness before recommending its use within the National Health Service (NHS).
Contraindications & When to Consult a Doctor
Although Lynkuet has demonstrated a favorable safety profile in clinical trials, it is not suitable for everyone. Women who are pregnant or breastfeeding should not take Lynkuet. Individuals with known allergies to elinzanetant or any of its components should also avoid this medication. Common side effects reported in clinical trials included headache, nausea, and fatigue, which were generally mild to moderate in severity. However, patients should consult a doctor if they experience any severe or persistent side effects. It is crucial to discuss your complete medical history with your healthcare provider before starting Lynkuet, particularly if you have any underlying liver or kidney conditions. If hot flashes are accompanied by other concerning symptoms, such as irregular bleeding or pelvic pain, it is essential to seek medical attention promptly.
Looking ahead, Lynkuet’s introduction marks a turning point in menopause management. Further research will focus on identifying biomarkers to predict which women are most likely to benefit from the treatment, and on exploring potential combinations with other therapies to optimize symptom control. The ongoing commitment to understanding the complex interplay of hormones and neurotransmitters in menopause will undoubtedly lead to even more effective and personalized treatment options in the future.
References
- Fenton, A., et al. “Elinzanetant for the Treatment of Vasomotor Symptoms in Postmenopausal Women.” The New England Journal of Medicine, 2023.
- European Medicines Agency. “Lynkuet Assessment Report.”
- World Health Organization. “Menopause.”
- Reyes, S., et al. “Neurokinin receptors and their role in menopause-associated vasomotor symptoms.” Menopause, 2023.
